Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-1896

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project ; day:22 ; month:11 ; year:2019 ; pages:1-13
Applied health economics and health policy ; (22.11.2019), 1-13

Creator: Standaert, Baudouin
Van Vlaenderen, Ilse
Van Bellinghen, Laure-Anne
Talbird, Sandra
Hicks, Katherine
Carrico, Justin
Buck, Philip O.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40258-019-00534-y

URN: urn:nbn:de:101:1-2020032607465752394782

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:59 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Standaert, Baudouin
Van Vlaenderen, Ilse
Van Bellinghen, Laure-Anne
Talbird, Sandra
Hicks, Katherine
Carrico, Justin
Buck, Philip O.
SpringerLink (Online service)

Other Objects (12)

Aufsatzsammlung

Vaccines for pandemic influenza

Aufsatzsammlung

Influenza vaccines for the future

Better influenza vaccines: an industry perspective

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

Constrained evolution drives limited influenza diversity

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea

Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines

Factors affecting the immunogenicity of influenza vaccines in human

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension

Aufsatzsammlung

Vaccines for pandemic influenza

Aufsatzsammlung

Influenza vaccines for the future

Better influenza vaccines: an industry perspective

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

Constrained evolution drives limited influenza diversity

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea

Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines

Factors affecting the immunogenicity of influenza vaccines in human

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension

Aufsatzsammlung

Vaccines for pandemic influenza

Aufsatzsammlung

Influenza vaccines for the future

Better influenza vaccines: an industry perspective

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

Constrained evolution drives limited influenza diversity

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea

Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines

Factors affecting the immunogenicity of influenza vaccines in human

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Vaccines for pandemic influenza

Influenza vaccines for the future

Better influenza vaccines: an industry perspective

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

Constrained evolution drives limited influenza diversity

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea

Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines

Factors affecting the immunogenicity of influenza vaccines in human

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension

Vaccines for pandemic influenza

Influenza vaccines for the future

Better influenza vaccines: an industry perspective

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

Constrained evolution drives limited influenza diversity

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea

Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines

Factors affecting the immunogenicity of influenza vaccines in human

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension

Vaccines for pandemic influenza

Influenza vaccines for the future

Better influenza vaccines: an industry perspective

Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?

Constrained evolution drives limited influenza diversity

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea

Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines

Factors affecting the immunogenicity of influenza vaccines in human

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension

Related objects

Reset password